TY  - JOUR
AU  - Borgonovo, Giulia
AU  - Vettus, Elen
AU  - Greco, Alessandra
AU  - Leo, Laura Anna
AU  - Faletra, Francesco Fulvio
AU  - Klersy, Catherine
AU  - Curti, Moreno
AU  - Valli, Mariacarla
PY  - 2022
DA  - 2022/4/21
TI  - Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Patients With Breast Cancer: Protocol for a Multi-Institutional Prospective Study
JO  - JMIR Res Protoc
SP  - e31887
VL  - 11
IS  - 4
KW  - breast cancer
KW  - cardiotoxicity
KW  - cardiac diagnostic imaging
KW  - radiotherapy
KW  - chemotherapy
AB  - Background: The incidence of breast cancer is rising worldwide. Recent advances in systemic and local treatments have significantly improved survival rates of patients having early breast cancer. In the last decade, great attention has been paid to the prevention and early detection of cardiotoxicity induced by breast cancer treatments. Systemic therapy-related cardiac toxicities have been extensively studied. Radiotherapy, an essential component of breast cancer treatment, can also increase the risk of heart diseases. Consequently, it is important to balance the expected benefits of cancer treatment with cardiovascular risk and to identify strategies to prevent cardiotoxicity and improve long-term outcomes and quality of life for these patients. Objective: This CardioTox Breast study aims to investigate the use of cardiac imaging, based on cardiac magnetic resonance and echocardiography, and to identify associated circulating biomarkers to assess early tissue changes in chemo-induced and radiation-induced cardiotoxicity in the time window of 12 months after the end of radiotherapy in patients with breast cancer. Methods: The CardioTox Breast trial is a multicenter observational prospective longitudinal study. We aim to enroll 150 women with stage I-III unilateral breast cancer, treated with breast conserving surgery, who planned to receive radiotherapy with or without systemic therapy. Baseline and follow-up data include cardiac measurements based on cardiac magnetic resonance imaging, echocardiography, and circulating biomarkers of cardiac toxicity. Results: This study details the protocol of the CardioTox Breast trial. Recruitment started in September 2020. The results of this study will not be published until data are mature for the final analysis of the primary study end point. Conclusions: The CardioTox Breast study is designed to investigate the effects of systemic and radiation therapy on myocardial function and structure, thus providing additional evidence on whether cardiac magnetic resonance is the optimal screening imaging for cardiotoxicity. Trial Registration: ClinicalTrials.gov NCT04790266; https://clinicaltrials.gov/ct2/show/NCT04790266 International Registered Report Identifier (IRRID): DERR1-10.2196/31887 
SN  - 1929-0748
UR  - https://www.researchprotocols.org/2022/4/e31887
UR  - https://doi.org/10.2196/31887
UR  - http://www.ncbi.nlm.nih.gov/pubmed/35451989
DO  - 10.2196/31887
ID  - info:doi/10.2196/31887
ER  -